Clinical Trials Logo

Filter by:
NCT ID: NCT03494036 Completed - Clinical trials for Connective Tissue Diseases

Effect of Synbiotic on Immune Response, Gut Permeability and Microbiota in Patient With Connective Tissue Disease

Start date: October 1, 2017
Phase: N/A
Study type: Interventional

This is a double blind randomized placebo controlled trial to determine the effect of synbiotic to FOXP3 regulatory T cells, IL-17, gut permeability and gut microbiota in patients with connective tissue disease. Synbiotic can increase FOXP3 regulatory T cells, decrease IL-17 and improve gut permeability and gut microbiota in patients with connective tissue disease.

NCT ID: NCT03489824 Recruiting - Clinical trials for Water Immersion Method Colonoscopy in Unsedated Patients

Effectiveness of RL- vs LL-starting Position in Unsedated Water Immersion Colonoscopy

RLPvsLLP
Start date: February 20, 2018
Phase: N/A
Study type: Interventional

Abdominal discomfort is of the most important patient interest when in an unsedated colonoscopy examination. Water method for colonoscopy examination has been studied widely and evidence showed effectiveness in reducing discomfort and increase cecal intubation time and increasing cecal intubation rates in unsedated patients.

NCT ID: NCT03474198 Completed - Clinical trials for Tuberculosis, Pulmonary

Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis

TRUNCATE-TB
Start date: March 21, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

The current standard management strategy for drug-sensitive pulmonary tuberculosis (TB) is to treat with multiple drugs for 6 months, although patients often fail to adhere to the long treatment, leading to poor clinical outcomes including drug resistance, which is expensive and difficult to treat. The TRUNCATE-TB trial evaluates an alternative strategy (the TRUNCATE-TB Management Strategy) comprising treatment for 2 months (8 weeks, extended to 12 weeks if inadequate clinical response) with a regimen predicted to have enhanced sterilising activity ("boosted regimen") and monitoring closely after treatment cessation. Those who relapse (predicted to be always drug sensitive and likely to occur early) will be retreated with a standard 6 month regimen. The trial is a randomized, open-label, multi-arm, multi-stage (MAMS) trial to test the hypothesis that the TRUNCATE-TB Management Strategy is non-inferior to the standard management strategy in terms of longer-term outcomes (clinical status at 96 weeks). If non-inferiority is demonstrated then the advantages/disadvantages of implementing the strategy will be explored in secondary outcomes (from patient and programme perspective). The trial will evaluate the TRUNCATE-TB Management Strategy with 4 potential boosted regimens (180 per arm, total 900 with the standard TB management strategy arm). The boosted regimens include new drugs (licensed drugs, repurposed from other indications) and optimized doses of standard drugs, selected based on consideration of maximal sterilising effect, absence of drug-drug interactions, as well as safety and tolerability over a period of 2 months

NCT ID: NCT03469869 Completed - Obesity Clinical Trials

Effects of Balanced and Sustainable Diet Application for Insulin Resistance and Inflammation Marker of Obese People

Start date: March 16, 2018
Phase: N/A
Study type: Interventional

This study evaluates the effect of balanced and sustainable diet application on fat composition, insulin resistance and inflammation marker in obese people. Intervention: Obese subject will receive intervention on balanced and sustainable diet application Control: Obese subject will receive a balanced diet application only

NCT ID: NCT03462108 Completed - Safety Issues Clinical Trials

Safety and Immunogenicity of Rotavirus (Bio Farma) Vaccine in Adults, Children & Neonates

Start date: April 9, 2018
Phase: Phase 1
Study type: Interventional

This study is to assess the safety of Rotavirus (Bio Farma) vaccine in adults, children and neonates.

NCT ID: NCT03460405 Completed - Safety Issues Clinical Trials

Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine in Indonesian Adults, Adolescents, Children and Infants

Start date: July 16, 2018
Phase: Phase 2
Study type: Interventional

This study is to assess the safety and immunogenicity of Vi-DT vaccine in adults, adolescent, children and infants.

NCT ID: NCT03455049 Completed - Increased Insulin Clinical Trials

The Effect of Andrographis Paniculata to GLP-1, Fasting Insulin, Insulin 2-h Post OGTT, and HOMA-IR

Start date: October 17, 2017
Phase: N/A
Study type: Interventional

Prevalence of type 2 diabetes have been increased, but medications had not been well, so that needed new alternatives. A new approach used in management of type 2 diabetes is incretin based therapy. Incretin hormone, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotrophic peptide (GIP), had producted in intestine due to carbohydrate intralumen. After had secreted, GLP-1 had degradated by DPP-4 enzyme till number and effect had been decreased. Decreasing of GLP-1 effect as main defect in type 2 diabetes. Andrographis paniculata (A. paniculata) as traditional treatment had known since years ago to have hypoglycemia effect. Extract of A. paniculata consists of andrographolid and flavonoid. Based on study of Wooten et al that flavonoid has hydroxyl to stimulate insulin's production through modulated GLP-1 receptor (GLP-1 receptor ligand). So the investigators need to study about The Effect of A. paniculata Extract to GLP-1, Fasting Plasma Insulin, Insulin concentrations measured during a standardized 2-h OGTT, and HOMA-IR.

NCT ID: NCT03453281 Completed - Clinical trials for Diabetic Retinopathy

Early Anatomical, Physiological, and Clinical Changes in Diabetic Macular Edema After Intravitreal Aflibercept Injection

Start date: October 10, 2017
Phase: Phase 4
Study type: Interventional

This is a one month pre post intervention study. Subjects with diabetic macular edema were given intravitreal anti VEGF (Aflibercept) injection. Central retinal thickness, macular electrophysiology, and visual acuity were observed one week and one month after injection was given to the eye to describe early anatomical, physiological, and clinical changes. We hypothesized that changes to these outcomes can be found and documented.

NCT ID: NCT03434197 Completed - Clinical trials for Osteoarthritis Knee Pain

Safety and Efficacy of SFPP in Knee Osteoarthritis

Start date: February 5, 2018
Phase: Phase 3
Study type: Interventional

The objectives of this study are to demonstrate the non-inferiority of esflurbiprofen plaster (SFPP) 40 mg applied for 2 weeks to diclofenac gel, the comparator, in terms of efficacy in patients with knee osteoarthritis (OA) and to examine the safety of SFPP.

NCT ID: NCT03431649 Completed - Clinical trials for Pediatric Pulmonary Hypertension

Efficacy of Beraprost in Lowering Pulmonary Arterial Pressure in Children

Start date: April 1, 2017
Phase: Phase 4
Study type: Interventional

To analyze the efficacy of beraprost and sildenafil for treatment of pulmonary hypertension in children with left to right shunt. analyze the efficacy and side effects.